Initial validation of a simulation model for estimating the impact of serogroup A Neisseria meningitidis vaccination in the African meningitis belt

The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries

(2018) Angela Y. Chang et al.   HEALTH AFFAIRS

Emergence of epidemic Neisseria meningitidis serogroup C in Niger, 2015: an analysis of national surveillance data

(2016) Fati Sidikou et al.   LANCET INFECTIOUS DISEASES

Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial

(2015) Charissa Fay Corazon Borja-Tabora et al.   BMC INFECTIOUS DISEASES

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt

(2015) Andromachi Karachaliou et al.   CLINICAL INFECTIOUS DISEASES

Meningococcal Meningitis Surveillance in the African Meningitis Belt, 2004–2013

(2015) Clément Lingani et al.   CLINICAL INFECTIOUS DISEASES

Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age

(2015) Milagritos D. Tapia et al.   CLINICAL INFECTIOUS DISEASES

Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso

(2015) Haoua Tall et al.   CLINICAL INFECTIOUS DISEASES

Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years

(2015) Aldiouma Diallo et al.   CLINICAL INFECTIOUS DISEASES

Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model

(2015) M. Jit et al.   BMJ-British Medical Journal

Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine

(2015) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model

(2015) M. Jit et al.   BMJ-British Medical Journal

Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study

(2013) DM Daugla et al.   LANCET

Identifying Optimal Vaccination Strategies for Serogroup A Neisseria meningitidis Conjugate Vaccine in the African Meningitis Belt

(2013) Sara Tartof et al.   PLoS One

Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data

(2012) Ryan T Novak et al.   LANCET INFECTIOUS DISEASES

Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience

(2012) Mamoudou H. Djingarey et al.   VACCINE

Validation of population-based disease simulation models: a review of concepts and methods

(2011) Jacek A Kopec et al.   BMC PUBLIC HEALTH

Baseline Meningococcal Carriage in Burkina Faso before the Introduction of a Meningococcal Serogroup A Conjugate Vaccine

(2011) Paul A. Kristiansen et al.   Clinical and Vaccine Immunology

Antibody Persistence after Serogroup C Meningococcal Conjugate Immunization of United Kingdom Primary‐School Children in 1999–2000 and Response to a Booster: A Phase 4 Clinical Trial

(2010) K. P. Perrett et al.   CLINICAL INFECTIOUS DISEASES

Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine

(2009) R. Borrow et al.   Clinical and Vaccine Immunology

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

(2008) Martin C. J. Maiden et al.   JOURNAL OF INFECTIOUS DISEASES